Developing innovative, safe and effective therapies is a challenge. Experience matters! Our Board has that experience and provides us with insight on how to maximize results, have a sense of urgency and accelerate the pipeline. By surrounding ourselves with these successful, experienced entrepreneurs, we maximize the potential for successful outcomes.
Glenn A. Oclassen Sr.
Glenn Oclassen has served as a member of our board of directors since December 2015. Prior to his retirement in October 2014, Mr. Oclassen was the President and Chief Executive Officer, and a director of Transcept Pharmaceuticals, Inc. from 2002 until the company merged with Paratek Pharmaceuticals. Mr. Oclassen was previously the founder, President and CEO of Oclassen Pharmaceuticals which was sold to Watson Laboratories in 1997. Mr. Oclassen holds a B.S. in zoology from San Diego State University.